5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼.


Journal

Photodiagnosis and photodynamic therapy
ISSN: 1873-1597
Titre abrégé: Photodiagnosis Photodyn Ther
Pays: Netherlands
ID NLM: 101226123

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 06 09 2019
revised: 12 11 2019
accepted: 05 12 2019
pubmed: 21 12 2019
medline: 18 12 2020
entrez: 21 12 2019
Statut: ppublish

Résumé

To investigate the diagnostic accuracy of 5- aminolevulinic acid-mediated photodynamic diagnosis (ALA-PDD) for upper urinary tract tumor (UTUC) including carcinoma in situ (CIS) lesions using flexible fluorescence ureterorenoscopy. A solution of ALA was orally administrated at 20 mg/kg body weight at 3 h prior to surgery. Fluorescence observation was carried out with IMAGE1S OPAL1 PDD system. Positive lesions that were identified as abnormal changes under white light and/or blue light were biopsied, followed by cold-cup biopsy of negative lesions that were normal-looking mucosa under white light and/or blue light. Diagnostic accuracy was analysed by comparing ureterorenoscopic observations under white light or blue light with pathological analysis results. A total of 31 biopsy specimens were obtained from 10 patients. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for PDD to detect UTUC was 100 %, 50 %, 52.4 % and 100 %, respectively. The sensitivity of PDD ureterorenoscopy was significantly higher than that of white light ureterorenoscopy by statistics (p < 0.05). Especially, 5 CIS lesions were detected only by ALA-PDD ureterorenoscopy (p < 0.05). Of 10 patients, one patient (10 %) experienced hypotension during the ALA-PDD. ALA-PDD for UTUC is a feasible and safe techniques with acceptable adverse events. Additional advantage of ALA-PDD for UTUC is the high sensitivity to detect CIS lesions with blue light mode.

Identifiants

pubmed: 31857216
pii: S1572-1000(19)30562-9
doi: 10.1016/j.pdpdt.2019.101617
pii:
doi:

Substances chimiques

Photosensitizing Agents 0
Aminolevulinic Acid 88755TAZ87

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101617

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest 5-aminolevulinic acid was provided by SBI Pharma CO., Ltd.

Auteurs

Hideo Fukuhara (H)

Departments of Urology, Kochi Medical School, Nankoku, Kochi, 783-8505, Japan. Electronic address: jm-fukuhara@kochi-u.ac.jp.

Atsushi Kurabayashi (A)

Departments of Pathology, Kochi Medical School, Nankoku, Kochi, 783-8505, Japan.

Mutsuo Furihata (M)

Departments of Pathology, Kochi Medical School, Nankoku, Kochi, 783-8505, Japan.

Shouhei Setuda (S)

SBI Pharmaceuticals Co., Ltd., Tokyo, Japan.

Kiwamu Takahashi (K)

SBI Pharmaceuticals Co., Ltd., Tokyo, Japan.

Kiyotaka Murakami (K)

SBI Pharmaceuticals Co., Ltd., Tokyo, Japan.

Toru Tanaka (T)

SBI Pharmaceuticals Co., Ltd., Tokyo, Japan.

Keiji Inoue (K)

Departments of Urology, Kochi Medical School, Nankoku, Kochi, 783-8505, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH